Biomolecular Imaging: A Convoluted Promise
This article was originally published in Start Up
Executive Summary
Interest in biomolecular imaging--the ability to study metabolic pathways and changes at the molecular level using in vivo imaging--is intense, particularly as pharmaceutical and biotech companies look for ways to improve the efficiency of their drug development processes. But, as a recent NIH-sponsored forum shows, the field has a number of hurdles--regulatory, technical, and organizational--to address before it becomes part of mainstream medicine.